Come to visit us on the EPO's stand at
Gene patents - patents on isolated genes (and proteins) with defined function(s) are patentable in Europe
Diagnostics - patents on diagnostics relating to measurements of natural phenomena are allowed in Europe
Personalised medicine - personalised medicine is patentable in Europe - come to our stand and find out what needs to be considered when filing such applications.
Second medical uses - a feature of the European
patent system that has no equivalent in the US - find out what evidence is needed at the filing date and what can be provided during the examination procedure to avoid risks and unpleasant surprises during prosecution.
Antibody patenting - the requirements under the European Patent Convention are considerably different compared to others, e.g. in the US – what are the differences and how does this affect your drafting of the application?
Patenting of software-related inventions (CII) in biotech – claims directed to subject matter which involves the use of a computer, computer network or other programmable apparatus are patentable under certain conditions.
Patenting of plants – latest changes to Rule 28(2) and recent decision of the board of appeal in T1063/18.
Pitfalls for US applicants when filing a patent at the EPO – general requirements apply under the EPC: priority entitlement, claim dependencies, added matter; there are also specific regulations for biotech applications that need to be observed.
For PCT international patent applicants, an EPO search is one of the most reliable and trustworthy assessments anywhere in the world 1 . Moreover, you can save on further search fees when your application later enters the European phase.
Over 130 countries acting as PCT receiving Offices allow applicants to choose the EPO as their search authority. They include the EPO's 38 member states, the USA, Japan, Brazil, India, Mexico, Singapore and South Africa.
Responding to a clear request from its applicants, the EPO has just changed the rules relating to further searches of non-unitary inventions. The new rules will ensure that all applicants benefit from equal treatment regarding the further prosecution of their application, especially in cases of non-unity.
This will give users more flexibility, allow them to save costs, and help the Office to offer equal service levels between the EP and PCT procedures. The changes are a demonstration of the EPO's on-going efforts to act dynamically and to respond to its applicants' needs.